Natural killer cells
Sponsors
Masonic Cancer Center, University of Minnesota, St. Jude Children's Research Hospital, Nationwide Children's Hospital, David Wald
Conditions
Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myeloid LeukemiaBreast CancerChronic Lymphocytic LeukemiaChronic Myeloid LeukemiaColorectal CancerEsophageal Cancer
Phase 1
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
CompletedNCT00303667
Start: 2005-01-31End: 2011-03-31Updated: 2017-12-28
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
CompletedNCT01576692
Start: 2012-04-30End: 2018-10-17Updated: 2018-11-15
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
RecruitingNCT04211675
Start: 2022-09-01End: 2027-12-31Target: 31Updated: 2025-05-13
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
SuspendedNCT05400122
Start: 2022-09-09End: 2026-06-01Target: 12Updated: 2025-11-12
Phase 2
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
CompletedNCT01105650
Start: 2010-07-31End: 2014-04-30Updated: 2017-12-28
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)
TerminatedNCT01106950
Start: 2010-07-31End: 2012-12-31Updated: 2017-12-28
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
CompletedNCT01181258
Start: 2010-08-31End: 2016-07-31Updated: 2018-02-06